World ADC Event London

World ADC Event London

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending the 14th Annual World ADC Event in London on 13th and 14th of March 2024.


Physiomics’ CEO, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event which is Europe’s definitive Antibody-Drug Conjugate meeting, attended by 600+ experts from the field. The aim is to engage with leaders from across the ADC industry to explore opportunities for collaboration where PKPD and QSP modelling techniques can be used to inform and de-risk development of ADCs to approval.


If you are interested in meeting at the World ADC Event London, please contact us through the conference app or email Hayley directly at


We look forward to seeing you there!



Physiomics plc

Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980


Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341


Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494



Notes to Editor


About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.